News articles about Myovant Sciences (NASDAQ:MYOV) have trended somewhat negative recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Myovant Sciences earned a news impact score of -0.05 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.7426662303753 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Separately, Zacks Investment Research lowered Myovant Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, May 3rd. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $18.20.

Shares of Myovant Sciences (NASDAQ MYOV) traded down 1.80% on Monday, hitting $11.46. The company had a trading volume of 10,584 shares. The company has a 50 day moving average of $11.47 and a 200-day moving average of $11.82. Myovant Sciences has a 12-month low of $10.14 and a 12-month high of $15.50. The company’s market cap is $690.81 million.

ILLEGAL ACTIVITY WARNING: “Myovant Sciences (NASDAQ:MYOV) Getting Somewhat Negative Media Coverage, Analysis Finds” was originally published by Daily Political and is owned by of Daily Political. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.dailypolitical.com/2017/08/07/myovant-sciences-nasdaqmyov-getting-somewhat-negative-media-coverage-analysis-finds.html.

About Myovant Sciences

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.